Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation | Zendy

Thomas A. Mavrakanas | Zendy; Katherine Garlo | Zendy; David M. Charytan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation

Author(s) -

Thomas A. Mavrakanas,

Katherine Garlo,

David M. Charytan

Publication year - 2020

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.11650919

Subject(s) - medicine , apixaban , atrial fibrillation , hazard ratio , stroke (engine) , dialysis , cardiology , retrospective cohort study , confidence interval , incidence (geometry) , warfarin , rivaroxaban , optics , engineering , mechanical engineering , physics

The relative efficacy and safety of apixaban compared with no anticoagulation have not been studied in patients on maintenance dialysis with atrial fibrillation. We aimed to determine whether apixaban is associated with better clinical outcomes compared with no anticoagulation in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research